LON:SKINIntegumen Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Integumen PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 2.05 +0.05 (+2.50 %) (As of 07/13/2020) Add Compare Share Today's Range 1.95Now: GBX 2.05▼ 2.2550-Day Range 1.74MA: GBX 1.89▼ 2.0352-Week Range 0.01Now: GBX 2.05▼ 2.19Volume23.25 million shsAverage Volume41,864 shsMarket Capitalization£22.11 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines Integumen Plc develops technologies for skin and health care, personal-hygiene, pharmaceutical, and cosmetic industries in the United Kingdom and Ireland. The company offers Labskin AI, a cloud-based eco-system, which validates skincare products and ingredients. It also provides a range of men's skincare products under the STOER brand. Integumen Plc was incorporated in 2016 and is based in Dalkey, Ireland.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Integumen. Previous Next 2.4 Community Rank Outperform VotesIntegumen has received 33 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIntegumen has received 35 “underperform” votes. (Add your “underperform” vote.)Community SentimentIntegumen has received 51.47% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Integumen and other stocks. Vote “Outperform” if you believe SKIN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SKIN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIntegumen does not currently pay a dividend.Dividend GrowthIntegumen does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Integumen insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Integumen is -6.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntegumen has a P/B Ratio of 4.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.48 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Household & Personal Products Sub-IndustryN/A SectorN/A Current SymbolLON:SKIN Previous Symbol CUSIPN/A CIKN/A Webwww.integumen.co.uk Phone+353-1-5373269Debt Debt-to-Equity Ratio16.14 Current Ratio1.76 Quick Ratio1.60Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£823,000.00 Price / Sales26.87 Cash FlowGBX 0.10 per share Price / Cash Flow19.75 Book ValueGBX 0.50 per share Price / Book4.10Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees11 Outstanding Shares1,078,749,952Market Cap£22.11 million Next Earnings DateN/A OptionableNot Optionable GBX 2.05 +0.05 (+2.50 %) (As of 07/13/2020) 30 days | 90 days | 365 days | Advanced Chart Receive SKIN News and Ratings via Email Sign-up to receive the latest news and ratings for SKIN and its competitors with MarketBeat's FREE daily newsletter. Integumen (LON:SKIN) Frequently Asked Questions How has Integumen's stock been impacted by COVID-19 (Coronavirus)? Integumen's stock was trading at GBX 1.18 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SKIN stock has increased by 74.5% and is now trading at GBX 2.05. View which stocks have been most impacted by Coronavirus. Has Integumen been receiving favorable news coverage? News stories about SKIN stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Integumen earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near future. View the latest news about Integumen. Who are some of Integumen's key competitors? Some companies that are related to Integumen include Mediland Pharm (MPH), Acme United (ACU), Warpaint London (W7L), Pental (PTL), BOD Australia (BDA), Brand Architekts Group (BAR), Orchids Paper Products (TIS), Skin Elements (SKN), Beiersdorf (BDRFF), Beiersdorf Aktiengesellschaft (BDRFY), Biologix Hair (BLGX), Dogness International (DOGZ), ESSITY AKTIEBOL/S (ESSYY), GreenBox POS (SHRG) and Henkel AG & Co KGaA (HEN3). View all competitors. What other stocks do shareholders of Integumen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Integumen investors own include AgroFresh Solutions (AGFS), Premier African Minerals (PREM), Greatland Gold (GGP), Jubilee Metals Group (JLP), Learning Technologies Group (LTG), Plains GP (PAGP), SolGold (SOLG), Tiziana Life Sciences (TILS), Alliance Resource Partners (ARLP) and Aquestive Therapeutics (AQST). Who are Integumen's key executives? Integumen's management team includes the following people: Mr. Gerard James Brandon, CEO & Director (Age 58)Mr. Camillus Gerard Glover, CFO, Director & Company Sec. (Age 58)Mr. Fionán Murray, COO & Director (Age 54)Mr. James O'Sullivan, Chief Technology OfficerMr. Colin O'Sullivan, Chief Information Officer What is Integumen's stock symbol? Integumen trades on the London Stock Exchange (LON) under the ticker symbol "SKIN." How do I buy shares of Integumen? Shares of SKIN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Integumen's stock price today? One share of SKIN stock can currently be purchased for approximately GBX 2.05. How big of a company is Integumen? Integumen has a market capitalization of £22.11 million and generates £823,000.00 in revenue each year. Integumen employs 11 workers across the globe. What is Integumen's official website? The official website for Integumen is www.integumen.co.uk. How can I contact Integumen? Integumen's mailing address is Dalkey, 19 Railway Road, DUBLIN, YO41 1LZ, Ireland. The company can be reached via phone at +353-1-5373269. This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
